Triple-Drug Microspheres Show Promise for Long-Term Glaucoma Neuroprotection

Glaucoma affects millions worldwide and remains a leading cause of irreversible blindness, primarily due to progressive damage to retinal ganglion cells and the optic nerve. Current treatments focus mainly on reducing intraocular pressure but often require frequent dosing and fail to address the underlying neurodegeneration.

Researchers developed innovative biodegradable microspheres made from poly(lactic-co-glycolic acid) (PLGA) that simultaneously deliver three complementary drugs: latanoprost (reduces eye pressure), melatonin (provides antioxidant protection), and ketorolac (reduces inflammation). The microspheres were designed to release these drugs continuously for months after a single intravitreal injection.

In laboratory studies, the optimized formulation showed excellent biocompatibility with retinal cells and sustained drug release over 70 days. When tested in rats with experimentally induced chronic glaucoma, animals receiving the triple-drug microspheres at 2 and 12 weeks showed remarkable improvements compared to untreated glaucomatous rats. Treated animals achieved the lowest intraocular pressures, enhanced function of both bipolar and retinal ganglion cells, and maintained greater neuroretinal thickness as measured by optical coherence tomography.

The results suggest this multi-target approach could revolutionize glaucoma treatment by addressing multiple disease mechanisms simultaneously while dramatically reducing dosing frequency. The sustained-release system could improve patient compliance and provide continuous neuroprotection, potentially slowing or preventing the vision loss that characterizes this devastating disease.

While promising, these findings require validation in human clinical trials before clinical application. The research represents a significant advance in developing comprehensive neuroprotective strategies for glaucoma and other neurodegenerative eye diseases.